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Abstract: Metastatic castration-resistant prostate cancer is commonly treated with chemotherapy,
whose effect is less than satisfactory. This raised the need for novel agents for the treatment of prostate
cancer. In the present study, five phthalimide-based curcumin derivatives were synthesized and
completely characterized to assess improved stability, pharmacodynamics, and radical scavenging
ability. To investigate the potential application in anti-cancer therapy, the anti-proliferative activity of
the synthesized molecules was determined on aggressive prostate tumor cells. We demonstrated that
the K3F21 derivative has increased potency compared to curcumin, in terms of GI50, anti-proliferative
and anti-migrating activities. K3F21 inhibits anchorage-dependent and -independent growth of
prostate cancer cells by altering the expression of key genes controlling cell proliferation, such as
Cylins D1, B1 and B2, and apoptosis, among which Puma, Noxa, and Bcl-2 family members. Finally,
the anti-cancer activity of K3F21 was demonstrated by the analysis of cancer-associated PI3K/AKT,
ERK, and p38 signaling pathways.
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1. Introduction
Prostate cancer (PCa) is the second most commonly diagnosed cancer and leading cause of
cancer death in western males [1]. The progression from normal prostate to prostatic intraepithelial
neoplasia (PIN) and localized adenocarcinoma occurs over many years. Adenocarcinoma is a
slow-growing tumor and progression to advanced and metastatic cancer is a relatively late process.
Androgen deprivation therapy (ADT), the gold standard for the treatment of advanced PCa, has
initial response rates of about 80–90%, but nearly all men eventually develop castration-resistant
PCa (CRPC), which is currently incurable [2]. CRPC is commonly treated with different approaches:
taxane chemotherapy (such as docetaxel and cabazitaxel), secondary hormonal therapeutic agents
(abiraterone and enzalutamide), cellular immunotherapy (sipuleucel-T), or radiotherapy (radium-223).
Despite this, inevitable progression of disease frequently occurs [3,4]. A considerable number of novel
agents are currently under investigation worldwide to cure PCa and metastatic CRPC [5].
Curcumin (1,7-bis [4-hydroxy-3-methoxyphenyl]-1,6-heptadiene-3,5-Dione), a polyphenol
obtained from the rhizome Curcuma longa L., and its analogs have shown anti-cancer properties
by suppressing tumor initiation and progression [6,7], through the modulation of multiple signaling
pathways and the inhibition of cell proliferation, invasion, metastasis, and angiogenesis [8].
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Curcumin has demonstrated chemopreventive and chemotherapeutic activity also in PCa. In vitro,
it reduces the expression of androgen receptors (AR), which appears to enhance the progression of
PCa to the hormone refractory state CRPC [9]. Experiments performed on LNCaP, PC3, and DU145,
metastatic PCa cells from lymph node, bone, and brain, respectively, showed that curcumin impacts
on cell proliferation by decreasing the expression of epidermal growth factor receptor (EGFR) and
cell cycle cyclins. Moreover, curcumin anti-proliferative activity has been associated to increased
expression of the cyclin dependent inhibitors (CDKs) p21, p27, and p16, both in vitro and in vivo.
Curcumin targets various signaling pathways, among which the PI3K/AKT network, commonly
constitutively activated in PCa (for a review see [10]). Interestingly, curcumin has been recently found
to affect cancer associated fibroblast (CAF)-driven PCa invasion, promoted by prostate tumor–stromal
interaction, through the inhibition of the MAOA/mTOR/HIF-1α signaling pathway [11]. These data
pointed at curcumin as a protective molecule against the epithelial to mesenchymal transition (EMT),
a highly complex process allowing the cells to escape from the primary tumor and disseminate at
distant sites.
Despite the proven efficacious anti-proliferative properties of curcumin against cancer cells
in vitro and in vivo, there is currently no approved health claim for this molecule [12]. The main
controversial dark side of this polyphenol is its apparent instability in physiological environment.
This limits a possible successful and controlled application in clinics and does not allow to fully
understand which mechanisms are activated by the molecule and which by its metabolites. It is
therefore crucial to identify stable derivatives and characterize their molecular basis of action against
cancer cell proliferation and metastatization. Recently, Nelson et al. [13] pinpointed the main concerns
in selecting curcumin as pharmaceutical lead compound. However, a wide slice of the scientific
community does not completely agree with this lapidary verdict [14–17]. In this landscape, we devoted
research efforts to develop new stable curcumin analogs based on phtalimide (K3F).
Phthalimide-based drugs firstly appeared in the late 1950s and Thalidomide, the most notable
one, was prescribed to pregnant women as a sedative and anti-emetic agent. The benefits of this
compound were soon darkened by the discovery of its teratogenicity that forced its withdrawal
from market. Today, Thalidomide is used in the treatment of erythema nodosum leprosum,
multiple myeloma, myelodysplastic syndrome, and shows promising properties in the treatment
of autoimmune disorders [18]. Recently, the identification of the basis for its teratogenicity has allowed
the development of new thalidomide derivatives without teratogenic activity [19]. Early clinical trials
showed that thalidomide has clinical anti-tumor activity in hormone-refractory PCa [20], therefore the
development of analogues and/or its administration in conjunction with other anti-cancer agents are
under exploration in order to improve its efficacy and reduce toxicity.
Here, we describe the synthesis, chemical and pharmacokinetic characterization, and
anti-proliferative activity of new phthalimide-based curcumin derivatives on human PCa cells.
2. Results
2.1. Synthesis and Characterization
The synthesis of curcumin-like structures is commonly performed by one-pot “Pabon
reaction” [21] or its modifications [22]. The reaction proceeds through the complexation of boron
by acetyl-acetone (acac), or another β-diketone, in order to protect the methylenic carbon and
activate the side methyl groups as nucleophiles. In a further step, Knoevenagel condensation takes
place with vanillin or other selected benzaldehydes. Finally, when the reaction is accomplished
in N,N-dimethylformamide (DMF), the product separates by acidification with hydrochloric acid.
In order to obtain the phthalimide-based curcuminoids (Figure 1), acac was functionalized by SN2
nucleophilic substitution catalyzed by K2CO3, and 2-(4-acetyl-5-oxohexyl)-1H-isoindole-1,3(2H)-dione
(1) was then used as reactant in the following Pabon reaction. With respect to acac, the presence of
phthalimide chain shifted the tautomeric equilibrium of compound 1 in favor of the β-diketo form,
Int. J. Mol. Sci. 2019, 20, 28 3 of 21
as a consequence boron complexation was slow and the protection step needed longer time (2 h vs.
30 min). The synthesized compounds, namely K3F, were isolated as yellow-orange powders by the
general synthetic scheme reported in Figure 1.
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Figure 1. General scheme for the synthesis of phthalimide-based curcuminoids. (a) K2CO3/KI, dry acetone, 80 
°C, 24 h; (b) B2O3, tributylborate, n-butylamine, DMF, 80 °C, 6 h; (c) 0.5 M HCl, 80 °C, 1 h. 
pH-metric titrations were performed in order to assess K3F acidity and predict the most abundant species 
in physiological condition. On increasing pH, a titration trend was observed for all the compounds, and, as 
reported for K3F21, the plot of A vs. pH at fixed λ highlighted the presence of at least one equivalent point 
(Supplementary Figure S1). Overall protonation constants (βHL) were calculated from spectrophotometric data 
and optimized by means of HypSpec software [15] (Supplementary Table S1). K3F23, K3F24 and K3F33 
behaved as weak monoprotic acids, with a pKa value close to 8–8.50 associated to the keto-enol moiety. As for 
the other two ligands, namely K3F21 and K3F31, the acid-base equilibria were more complex in view of the 
polyprotic nature of the compounds, and three logβLH values were calculated. Species distribution curves 
(Supplementary Figure S2) provided reliable prediction of neutral and charged forms as function of pH, and 
consequently helped to envisage cell penetration and distribution in physiological conditions. For monoprotic 
acids K3F23, K3F24, and K3F33, the prevailing species at pH 7 was the neutral one (HL). As for K3F21 and 
K3F31, they behaved as less weak acids, in fact at pH 7 58% of K3F21 and 65% of K3F31 were found in the 
mono-dissociated negatively charged form (H2L-), these percentages increased up to 74% and 86% respectively 
at pH 7.4. K3F31 resulted to be more dissociated than K3F21 at the same pH, hence more acid. This outcome 
could be attributed to the stabilizing effect of the intramolecular hydrogen bond between the methoxyl and 
hydroxyl groups on the aromatic ring in the indissociated form of K3F21, which shifts the equilibrium in favor 
of the neutral species (H3L). 
The coupling of curcumin backbone with phtalimide moiety improved stability with respect to the lead 
molecule that degrades up to 40% within the first hour [23], in particular K3F33 was the most stable compound 
of the series, with a residual percentage close to 60% after 24 h (Figure 2A). 
The phenolic derivatives K3F21 and K3F31 were tested for their radical scavenging ability by DPPH assay 
(Figure 2B). Both K3F21 and K3F31 exerted radical scavenging activity against DPPH radical, however K3F21 
was more effective as suggested by IC50 values (24 µM vs. 120 µM). The intramolecular hydrogen bond 
between the phenolic hydrogen and the methoxyl oxygen seems to be a conditio sine qua non for the formation 
of a stable radical species. 
Figure 1. General scheme for the synthesis of phthalimide-based curcuminoids. (a) K2CO3/KI, dry
acetone, 80 ◦C, 24 h; (b) B2O3, tributylborate, n-butylamine, DMF, 80 ◦C, 6 h; (c) 0.5 M HCl, 80 ◦C, 1 h.
pH-metric titrations were performed in order to assess K3F acidity and predict the most abundant
s ecies in physiological condition. On increasing pH, a titration trend was observed for all the
compounds, and, as reported for K3F21, the plot of A vs. pH at fixed λ highlig ted the presence
of at least one equivalent point (Supplementary Figure S1). Ov rall pr tonation constants (βHL)
were calculated from spectrophot metric data and optimized by means of HypSpec software [15]
(Supplementary Table S1). K3F23, K3F24 nd K3F33 behaved as weak monoprotic acids, with pKa
value clos to 8–8.50 asso i te to the keto-enol moiety. As for the other two ligands, nam ly K3F21 and
K3F31, the acid-base equilibria were more complex in view of the polyprotic natur of the compounds,
and three logβLH values were calculated. Species distribution curves (Supplementary Figure S2)
provided reliable prediction of neutral and charged forms as function of pH, and conseq ently helped
to envisage cell penetration and distribution in physiological co ditions. For monoprotic acids K3F23,
K3F24, and K3F33, the prevailing species at pH 7 was the neutral one (HL). As for K3F21 and K3F31,
they behaved as less weak acids, in fact at pH 7 58% of K3F21 and 65% of K3F31 were found in the
mono-dissociat d negatively charged form (H2L−), these percentag s increased up to 74% and 86%
respectively at pH 7.4. K3F31 resulted to be more dissociated than K3F21 at the sa e pH, hence more
acid. This outcome could be attribut d t the stabilizing effect of the intramolecular hydrogen b nd
between the methoxyl and hydroxyl groups on the aromatic ring in the indi sociated form of K3F21,
which shifts the equilibrium in favor of the neutral species (H3L).
The coupling of curcumin backbone with phtalimide moiety improved stability with r spect to
the l ad molecule that degrades up to 40% within the first hour [23], in particular K3F33 was the most
stable compound of the series, with a residual percentage close to 60% after 24 h (Figure 2A).
T phenolic derivatives K3F21 and K3F31 were tested fo their radical scavenging ability by
DPPH assay (Figure 2B). Both K3F21 and K3F31 exerted r dical scave ging activity against DPPH
radical, however K3F21 was more effectiv as suggested by IC50 valu s (24 µM vs. 120 µM). The
intramolecular hydrogen bond between the phenolic hydrogen and the methoxyl oxygen seems t be
a conditio sine qua non for the formation of a stable radical species.
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Figure 2. Stability and radical scavenging ability of K3F derivatives. (A) Residual % of K3F compounds vs. time 
(PBS 0.01 M, NaCl 0.1M, pH = 7.4, 37 °C in darkness). Residual % is calculated as At·100/A0, where At and A0 
stand for absorbance at λmax at time t and time zero, respectively. (B) Percentage of inhibition of free DPPH 
radical ([DPPH·] = 60 µM) in the presence of K3F compounds at increasing concentrations. Compounds 
concentration is expressed as molar ratio (compound/DPPH). 
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To investigate the potential anti-tumor activity of the new synthesized molecules, we tested their effect 
on the proliferation of cancer cell lines, in particular PC3 and DU145, two of the most representative in vitro 
models of PCa, in which AR is not expressed. Dose–response assays were performed with K3F21, K3F23, 
K3F24, and K3F33 (Figure 3A,B) and GI50 values were determined as the concentration that causes 50% 
growth inhibition following 48 h of treatment (Figure 3C). The comparison between curcumin and K3F-
derivatives highlighted that the addition of phthalimide significantly enhances the anti-proliferative activity 
of K3F21 and K3F23 in PC3 and DU145 cells (Figure 3C). Similarly, we tested the activity of the compounds in 
another cancer cell line, the colon carcinoma HCT116 cells, in which the effect of curcumin has been largely 
investigated and characterized [24]. Also in these cells, K3F21 is the most active molecule compared to the 
other derivatives (Supplementary Figure S3A,B). 
Figure 2. Stability and radical scavenging ability of K3F derivatives. (A) Residual % of K3F compounds
vs. time (PBS 0.01 M, NaCl 0.1M, pH = 7.4, 37 ◦C in arkness). Residual % is calculated as At·100/A0,
where At and A0 stand for absorbance at λmax at time t and time zero, respectively. (B) Percentage of
inhibition of free DPPH r dical ([DPPH·] = 60 µM) in the presence of K3F compou ds at i creasing
oncentrations. Compounds concentration is expressed as molar ratio (compound/DPPH).
2.2. Phthalimide-Based Curcumin Derivatives Decrease Viability of Human Cancer Cells
To investigate the potential anti-tumor activity of the new synthesized molecules, we tested
their effect on the proliferation of cancer cell lines, in particular PC3 and DU145, two of the most
representative in vitro models of PCa, in which AR is not expressed. Dose–response assays were
performed with K3F21, K3F23, K3F24, and K3F33 (Figure 3A,B) and GI50 values were determined
as the concentration that causes 50% growth inhibition following 48 h of treatment (Figure 3C). The
comparison between curcumin and K3F-derivatives highlighted that the addition of phthalimide
significantly enhances the anti-proliferative activity of K3F21 and K3F23 in PC3 and DU145 cells
(Figure 3C). Similarly, we tested the activity of the compounds in another cancer cell line, the
colon carcinoma HCT116 cells, in which the effect of curcumin has been largely investigated and
characterized [24]. Also in these cells, K3F21 is the most active molecule compared to the other
derivatives (Supplementary Figure S3A,B).
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Figure 3. Dose-dependent effect of K3F-derivatives on PCa cells. Cell growth of PC3 (A) and DU145
(B) prostate cancer cells was assessed by MTT assays following 48 h treatment with the indicated
molecules. Data are presented as relative cell viability (%) of treated cells versus DMSO control cells,
arbitrarily set at 100%. The bars represent the mean of four independent experiments ± SEM. GI50
values, SEM and statistical significance compared to curcumin have been indicated for PC3 (C) and
DU145 (D). p values * < 0.05, **** < 0.0001, NS = not significant.
To determine whether K3F-derivatives could have cytotoxic rather than cytostatic activity, we
analyzed the distribution of the cells within the different phases of the cell cycle following the
administration of the molecules at GI50 doses for 48 h (Figure 4 and Supplementary Figure S4A,B).
In PC3 cells, curcumin administration resulted in an evident increase of the G2/M population, which
raised from about 19% in control cells (DMSO) to 37% in treated cells. Similarly, K3F21, K3F23, K3F24,
and K3F33 doubled the percentage of G2/M cells, highlighting a cytostatic activity of the molecules.
Only the administration of curcumin and K3F33 significantly increases SubG1 events, indicative of
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cell death (Figure 4A). As for DU145, curcumin mainly acts as a cytotoxic drug, as indicated by the
significant increase of SubG1 events from 1.75% to 5% in control and treated cells, respectively. K3F24
and K3F33 showed the ability to arrest cell cycle progression, while K3F21 and K3F23 both arrested
the G2/M progression and induced cell death (Figure 4B).
Figure 4. Effects on cell cycle progression of K3F derivatives. Cell distribution between cell cycle
phases following administration for 48 h of DMSO, Curcumin or the indicated K3F-derivatives on
PC3 (A) and DU145 (B) prostate cancer cells at GI50 concentrations. The bars represent the mean
of three independent experiments ± SEM. Representative images of cell cycle analysis are shown
in Supplementary Figure S4. p values refer to the comparison between K3F-derivatives and DMSO
samples: * < 0.05, ** < 0.01, **** < 0.0001.
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The semisynthetic taxane docetaxel (DTX), chemotherapeutic agent approved by FDA for its
ability to prolong survival in patients with metastatic CRPC [25], was used as positive anti-proliferative
compound. As expected, DTX administration at GI50 dose showed a high cytotoxic effect associated
to a robust increase in SubG1 events (Supplementary Figure S4C,D).
K3F-derivatives were also tested in HCT116 cells: all the molecules induced a significant increase
in SubG1 events (Supplementary Figure S3C).
Taking into consideration that all K3F-derivatives showed anti-proliferative effects, but K3F21 is
the molecule with the lowest GI50 value in all the tested cell lines, we decided to further investigate its
molecular activity as anti-cancer drug in PCa cells.
2.3. K3F21 Administration Modulates the Transcription of Genes Involved in PCa Cell Growth
The anti-proliferative and pro-apoptotic activity of curcumin on PCa cells was previously
reported [10,26–28]. Among the mechanisms through which curcumin impacts on PCa proliferation,
transcriptional modulation of genes controlling cell cycle progression and apoptosis has been described
in vitro and in vivo (reviewed in [10]). We therefore decided to investigate the transcriptional effect of
K3F21 administration on these processes in PC3 and DU145 cells, analyzing selected representative
target genes. In both cell lines, we observed a general decrease, though not always significant, in
the transcription of Cdc2, CyclinB1, CyclinB2, and CyclinD1 cell cycle genes in K3F21-treated cells
compared to curcumin and control cells (Figure 5). The transcription of genes encoding CDK inhibitors
p21 and p27 similarly increased following curcumin and K3F21 administration in PC3 cells, while
they raised only after K3F21 treatment in DU145 cells. These results are consistent with cell cycle
analysis (Figure 4), showing that curcumin and K3F21 similarly arrested cell cycle progression in PC3
cells, while only K3F21 induced a G2/M block in DU145 cells. The analysis of EGFR, linked to the
proliferation of PCa cells, highlighted that its expression is reduced by K3F21 only in DU145 cells.
Finally, we analyzed few apoptotic genes, such as the pro-apoptotic Noxa, Puma, and Bad, and the
anti-apoptotic Bcl-2 and Bcl-xl genes. While Noxa was induced by K3F21 as well as curcumin, Puma
increased exclusively following K3F21 administration, in both PCa cells. As for anti-apoptotic genes,
different transcriptional programs were activated in the two cell lines: Bcl-2, but not Bcl-xl, was weakly
repressed by K3F21 in PC3, as opposed to DU145.
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Figure 5. Effect of curcumin and K3F21 on gene transcription. RT-qPCR on PC3 (A) and DU145
(B) prostate cancer cells treated with DMSO, curcumin and K3F21 for 48 h at GI50 doses. Data
are presented as relative transcript levels, normalized with RPL21 housekeeping gene, with DMSO
levels arbitrarily set at 1. The bars represent the means of three independent experiments ± SEM.
p values refer to the comparison between curcumin and K3F21 with DMSO samples: * < 0.05, ** < 0.01,
**** < 0.0001.
2.4. K3F21 Affects the Key Molecular Pathways Promoting PCa Progression
Multiple intracellular signaling pathways implicated in PCa progression are modulated by
anti-cancer drugs, as corroborated by the analysis of whole cellular extracts from DTX-treated PCa
cells (Supplementary Figure S5). By western blot analysis, we determined whether K3F21 is able to
inhibit the activation of receptor tyrosine kinase signaling (Figure 6A).
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Firstly, we studied the effect of K3F21 administration on PI3K/AKT pathway activation,
significantly deregulated in PCa [29]. Both curcumin and K3F21 inhibited the phosphorylation of AKT
in Ser473 and Thr308 in PC3 cells [30]. We were not able to detect AKT phosphorylation in DU145
cells, presumably due to the presence of the oncosuppressor PTEN that minimizes endogenous AKT
activation [30]. Administration of chemotoxic drugs has been shown to induce ERK phosphorylation,
and an inverse relation seems to link ERK and AKT activity in PCa [30–32]. Western blot analysis
showed that both curcumin and K3F21 increased ERK1/2 phosphorylation in PC3 and, more evidently,
in DU145 cells, likely as a consequence of reduced basal levels of PI3K/AKT activity [30].
Finally, p38 phosphorylation was investigated as important mechanism mediating cellular
pro-inflammatory responses in PCa [10]. The administration of K3F21, but not curcumin, inhibited
phospho-p38 expression in PC3, while no changes were observed in DU145 cells.
We also analyzed the effect of the molecules on the expression of γH2AX, as a marker of DNA
damage commonly activated by chemoterapeutic drugs (Figure 6B). While curcumin increased γH2AX
in PC3 only, K3F21 triggered DNA damage in both PC3 and DU145 cells, indicating a genotoxic
effect independent from the status of p53. Indeed, the oncosuppressor p53, involved in DNA damage
response, is not expressed in PC3 and mutated in its activity in DU145 cells. Moreover, the evaluation
of PARP-1 cleavage corroborated the activation of apoptotic cell death following K3F21 administration
only in DU145 cells, as already observed by cell cycle analysis (Figure 4).
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Figure 6. Effects of K3F21 on PCa promoting pathways. Total cellular lysates from PC3 and DU145 cells
treated with DMSO, curcumin and K3F21 for 48 h at GI50 doses were analyzed by western blot with
the indicated antibodies involved in receptor tyrosine kinase signaling (A) or DNA damage pathways
(B). Actin was used as loading control.
2.5. K3F21 Inhibits Metastatic Ability of PCa Cells to Migrate and Proliferate
Increased cell motility of cancer cells, among which PCa cells, strongly impacts on their metastatic
potential. We therefore tested whether K3F21 could decrease the migration ability of PC3 and DU145
cells, characterized by high metastatic potential. In vitro wound assays were performed and cell
migration of curcumin and K3F21-treated cells was calculated as percentage of wound recovery
compared to control cells. As shown in Figure 7, while DMSO-treated cells filled about 100% of
Int. J. Mol. Sci. 2019, 20, 28 10 of 21
the wound area, K3F21 exerted inhibitory effects on the migratory capacity of PCa cells, similarly
to curcumin. Interestingly, K3F21 showed more potent anti-migration activity compared to DTX,
commonly used in anti-cancer clinical therapy.
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Figure 7. Inhibition of cell migration by curcumin, K3F21 and DTX. The percentage of wound recovery
was assessed following DMSO, curcumin, K3F21 and DTX administration at GI50 doses in PC3 (A) and
DU145 (B) after 40 and 16 h, respectively. Representative images are shown in lower panels. p values
* < 0.05, ** < 0.01.
Next, we performed a clonogenic assay, based on the ability of a single cell to grow into a colony,
to determine the effectiveness of the anti-proliferative activity of K3F21 to inhibit cell growth of PCa
cells also in this condition. Plated PC3 and DU145 cells were treated with different doses of curcumin
and K3F21 and the number of colonies were counted following 7 or 10 days, respectively, and reported
as percentage vs. DMSO control cells. K3F21 clearly inhibited cell growth when administered at lower
concentrations than curcumin, in both cell lines (Figure 8A,B). Interestingly, despite the GI50 value of
K3F21 in traditional 2D monolayer PC3 culture was established as about 10 µM, colony formation was
quite completely abolished already at 5 µM, at least in PC3 cells.
Finally, we investigated whether K3F21 was able to inhibit the proliferation of PCa cells when
cultured in suspension within a semi-solid gel. The ability to grow in the absence of anchorage to the
extracellular matrix (anchorage-independent condition) is one of the hallmarks of malignancy and is
crucial in the tumor progression. The decrease in colony formation reached up to 95% following K3F21
treatment at 5 and 10 µM in PC3 and DU145 cells, respectively (Figure 8C,D, Supplementary Figure
S6). In PC3 cells, we observed enhanced anti-tumor activity of K3F21 compared to curcumin: similar
effects were induced by curcumin when administered at 10 and 20 µM compared to K3F21 5 µM.
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2.6. K3F21 Enhances Anti-Tumor Activity of Docetaxel in DU145 Cells
The combination of DTX with other anti-proliferative molecules has been proposed as a promising
strategy for enhancing the sensitivity to chemotherapy in CRPC. Curcumin co-administration to
DTX was shown to increase the anti-proliferative activity of the two molecules with respect to
single treatments. In particular, their combination modulates the expression and activity of proteins
commonly hyper-activated in PCa [33]. We therefore decided to investigate the effect of K3F21
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co-administration with DTX on PC3 and DU145 cells (Figure 9). Treatment with DTX resulted in a
dose-dependent decrease in cell viability of PCa cells. In DU145 cells, co-administration of K3F21 and
DTX 20nM for 48 h induced a significant decrease in cell viability compared to independent treatments
with DTX or K3F21. The determination of the Combination Index (CI) [34] revealed a slight synergism
(CI = 0.8) between the drugs with a DTX drug reduction index (DRI) of 2.9, hinting that concurrent
administration with K3F21 could allow an effective reduction of DTX dose. Differently, none of the
evaluated K3F21/DTX combinations affected cell growth when compared simultaneously to both DTX
and K3F21 single administration in PC3 cells.
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3. Discussion
In preclinical models, thalidomide and its derivatives have shown growth inhibition and enhanced
susceptibility to apoptosis of tumor cells [35]. However, in terms of the achieved response rates, i.e., the
percentage of patients whose c ncer shrinks or disappears after treatment, thalidomide showed mild
activity towards CRPC. Phase II clinical trial showed that about 30–40% of pati nts with metast ic
CRPC h d a declin in PSA of ≥40%, associated w th an improvement of clinical symptoms, following
thalidomide treatment [36,37].
As regards curcumin, several studies have shown its potential therapeutic effects on PCa cells
survival, both in vitro and in vivo [16,26,27,38]. In particular, the activity of curcumin has been
well describe on PC3 cell , accepted n vitro model of highly aggressiv prostate cancer [16,39].
Nevertheless, the growth suppressive activity and bioavailability of c rcumin in humans showed
limitations for its use as an effective therapeutic agent in c ncer. Therefore, the conjugation of
phtalimide with curcumin nd its derivatives could represent a successful strategy o d velop
new multi-t rget derivatives to defeat PCa. In add tion, as previously observed for other β-diketo
substituted curcuminoids [22], the presence of a bulky s bstituent in α position t th ke o-enol moiety
shifts the equilibrium towards the diketo form, improving stability and pot ntially bioavailability.
K3F33, K3F23, and K3F24 show an acid-base b hav o si ilar to curcumin, with a typical pKa value
rangi g from 8 to 8.5 tha can be attributed to the dissociation of enol proton. Diffe ently, as suggested
for other curcuminoids [40], the low value of the firs pKa for K3F21 and K3F31 could be reasonably
attributed to the phenol group, which acidity is decreased by the conjugated keto-enol group in para
position. For these compounds, the second pKa is due to the keto-enol moiety, and the last one to the
second phenolic group.
This study reports on the synthesis, chemical and biological characterization of the phthalimide-based
curcuminoids as new potential therapeutic molecules in PCa. Chemical characterization and in vitro data
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on tumor cell lines identified K3F21 as the most attracting molecule for further cellular and molecular
characterization of its anti-proliferative activity. In fact, K3F21 is a weak acid that is indissociated in
physiological condition, hence present in its neutral form. The high lipophilicity (data not shown)
together with its low molecular mass allow to predict high bioavailability. The presence of phtalimide
moiety stabilizes the diketo tautomer, improving on one hand pharmacokinetics with respect to
curcumin and maintaining similar radical scavenging activity on the other. K3F21 shows higher
efficacy in terms of growth inhibitory activity (GI50) compared to curcumin, not only in PCa cells
but also in human colon adenocarcinoma cells. Although K3F21 has a similar GI50 concentration
on PC3 and DU145 cells, it exerts different anti-proliferative effects in the two cell lines. While its
administration to PC3 significantly increases the G2/M population, without inducing cell death,
DU145 treated cells shows both G2/M cell cycle arrest and apoptosis (Figure 4). The analysis by
western blot of cleaved-PARP1 suggests the activation of a caspase-mediated cell death (Figure 6).
PC3 and DU145 cells are characterized by non-luminal-like phenotypes and are representative
of aggressive disease, with similarity in overall gene expression [41]. Indeed, the analysis of single
gene transcription, performed by RT-qPCR, highlighted the activation of quite similar transcriptional
programs by curcumin and K3F21 in the two cell lines (Figure 5). Despite this, we should consider
that PC3 and DU145 cells differ in the status of the p53 gene, which encodes for a transcription
factor involved in the response to cellular stresses, DNA damage, and cytotoxic drugs. During PCa
progression, epithelial cells acquire different mutations in key genes controlling cell proliferation
and cell survival, among which p53 [42]. In particular, mutations that give rise to mutant gain of
function (GOF) or dominant negative (DN) p53 allow the tumor to survive anticancer therapies [43].
The administration of DNA damaging agents to mutant p53 cells may potentially further increase
cancer progression: mutant p53 cells usually escape cell cycle arrest following DNA damage, which
eventually triggers the acquisition of more mutations allowing cancer cell survival. While PC3 cells
are p53-null, therefore they do not express p53 at the protein level, DU145 cells express mutant DN
p53 (P223L/V274F) [44,45]. K3F21 efficiently inhibits cell proliferation in DU145 as well as in PC3 cells
when cultured in normal 2D conditions. Differently, curcumin and K3F21 activities on cell migration
and colony formation in anchorage-independent condition, key futures of cancer cells, highlighted
the increased sensitivity of PC3 cells vs. DU145 cells towards curcumin and K3F21 (Figure 8). It is
interesting to note that in 3D culturing conditions, that better mimic the physiological in vivo tumor
growth condition, K3F21 is more active than in normal 2D monolayer culture conditions.
Finally, we should also consider the status of the PTEN/PI3K/AKT axis in the examined cells.
PTEN is one of the anti-apoptotic genes frequently mutated in PCa: while PC3 are PTEN-negative,
DU145 cells possess the functional protein. This difference plays a great role in the activation of the
PI3K/AKT and ERK pathways: PTEN expression in DU145 cells minimizes aberrant activation of
PI3K/AKT, which is sufficient for upregulation of ERK phosphorylation. ERK activation seems to be
necessary for drug-induced death and its inactivation has been identified as a hallmark of advanced
PCa [31,32,46]. Consistent with these published data, our western blot analysis highlighted that
K3F21-induced inhibition of AKT phosphorylation is associated with increased ERK activation in both
PC3 and DU145 cells (Figure 6).
Treatment of PCa cells with DTX inhibits their proliferation and activates apoptosis. Since
curcumin has been recently shown to increase the efficacy of DTX treatment in PCa [33], we
decided to investigate the effect of K3F21 and DTX combination. In DU145 only, we were able
to quantitatively determine synergism with CI<1 between the two molecules. Moreover, the favorable
DTX dose-reduction index (DRI) suggested the promising potentiality of K3F21 as a therapeutic adjunct
with DTX in the treatment of PCa. Further studies will help to elucidate why this effect is observed
only in DU145 and not in PC3 cells.
Overall, our results indicate that K3F21 exhibits similar or more potent activity than curcumin
in the inhibition of prostate cancer cell growth and migration, as well as in the modulation of key
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molecular pathways involved in tumor progression and survival. These results open the opportunity
to develop K3F21 molecule as a new therapeutic drug in aggressive PCa tumors.
4. Materials and Methods
4.1. General Procedures and Chemicals
Elemental analysis was performed on Thermo ScientificTM FLASH 2000 organic elemental
analyzer. The percentage of C, H, and N were experimentally calculated. Liquid chromatography/mass
spectrometry (LC/MS) was performed on Agilent 6300 Ion Trap LC/MS System equipped with an
electrospray ionization (ESI) interface. The compounds were separated using Agilent Zorbax SB C18 30
× 2.1 mm, 3.5 µm. Samples were prepared in MeOH and diluted to 10 ppm in MilliQ water; blank was
MilliQ water. Eluent phase: pump A H2O (formic acid 1%), pump B ACN (formic acid 1%), gradient:
10% of B for 1 min, 10–100% of B for 5 min, then 100% of B for 4 minutes, flux 0.3 mL/min, injection
volume 10 µL. The ion spectra were obtained in positive mode, using a scan range between 100 and
1500 m/z. High-purity nitrogen was used as nebulizer and drying gas (flow rate 10 L/min, 350 ◦C).
The nebulizer gas pressure was 32 psi and the capillary voltage was 3.5 kV. All reagent grade chemicals
were purchased from Sigma-Aldrich (St. Louis, MO, USA) and used without further purification unless
otherwise specified. NMR spectra were recorded on a Bruker FT-NMR AVANCE III HD 600 MHz
spectrometer with 5 mm CryoProbe BBO H&F at 298 K. Nominal frequencies were 600.13 MHz for
1H and 150.9 MHz for 13C. For each sample, ~5 mg were weighed and diluted up to 0.6 mL with
the proper deuterated solvent into 5 mm NMR tube. 90◦ pulse was calibrated for each sample and
standard NMR parameters were used to achieve quantitative results (relaxation delay 10 s). Proton and
carbon chemical shifts are given in parts per million (ppm) vs. external TMS, and were determined by
reference to the solvent residual signals. Typical 2D homo- and hetero-nuclear techniques were used
for assignment, i.e., 1H,1H-COSY, 1H,13C-HSQC, 1H,13C-HMBC. The purity of all final compounds
was determined to be at least 95% pure by a combination of LC-MS, NMR, and combustion analysis.
4.2. Synthesis
2-(4-acetyl-5-oxohexyl)-1H-isoindole-1,3(2H)-dione (1), (2-((4Z,6E)-5-hydroxy-7-(4-hydroxy-3-
methoxyphenyl)-4-((E)-3-(4-hydroxy-3-ethoxyphenyl) acryloyl) hepta-4,6-dien-1-yl)isoindoline-1,3-dione
(K3F21) and 2-((4Z,6E)-4-cinnamoyl-5-hydroxy-7-phenylhepta-4,6-dien-1-yl)isoindoline-1,3-dione
(K3F33) were synthesized and characterized as previously reported by the authors [47].
The same procedure was applied for the synthesis of K3F23, K3F31 and K3F24 that are here
completely characterized.
(2-((4Z,6E)-5-hydroxy-7-(3-methoxyphenyl)-4-((E)-3-(4-hydroxy-3-ethoxyphenyl) acryloyl) hepta-4,
6-dien-1-yl)isoindoline-1,3-dione (K3F23). Yellow powder, yield 30%. Elemental analysis for
C32H29NO6 (523.58 g/mol): calc. C 73.41% H, 5.58%, N 2.69%; found: C 73.62%, H 5.62%, N 2.60%.
LC-MS (ESI): m/z 524.6 [M + H]+. 1H NMR (MeOD-d4) δ keto-enol form: 7.19 (H-3, d (3JHH 15.3), 2H),
7.70 (H-4, d (3JHH 15.3), 2H), 7.21 (H-6, d (3JHH 8 Hz), 2H), 7.00 (H-8, dd, (3JHH 8 Hz; 4JHH 2 Hz) 2H),
7.20 (H-9, m, 2H), 7.31 (H-10, m, 2H), 2.71 (H-11, t (3JHH 7 Hz), 2H), 1.98 (H-12, m, 2H), 3.86 (H-13, t
(broad), 2H), 7.89 (H-16, m, 2H), 7.82 (H-17, m, 2H). 13C NMR (MeOD-d4) δ 110.6 (C-1), 183.2 (C-2),
119.4 (C-3), 142.0 (C-4), 134.2 (C-5), 112.6 (C-6), 160.1 (C-7), 116.7 (C-8), 129.8 (C-9), 120.2 (C-10) 23.7
(C-11), 31.6 (C-12), 38.3 (C-13), 168.6 (C-14), 134.8 (C-15), 123.4 (C-16), 134.7 (C-17).
(2-((4Z,6E)-5-hydroxy-7-(4-acetyl-3-methoxyphenyl)-4-((E)-3-(4-hydroxy-3-ethoxyphenyl)
acryloyl) hepta-4,6-dien-1-yl)isoindoline-1,3-dione (K3F24). Light orange powder, 45% yield.
Elemental analysis for C36H33NO10: calc. C 67.60%, H 5.20%, N 2.19%; found C 67.25%, H 5.35%, N
2.15%. LC-MS-IT m/z 640.8 (M + H)+. 1H NMR (CDCl3): 7.02 (H-3, d (3JHH 15.6 Hz), 2H), 7.76 (H-4, d
(3JHH 15.6 Hz), 2H), 7.24 (H-6, d (3JHH 7.8 Hz), 2H), 7.10 (H-9, d (3JHH 7.8 Hz), 2H), 7.21 (H-10, dd
(3JHH 7.8 Hz, 4JHH 3 Hz), 2H), 2.65 (H-11, t (3JHH 7 Hz), 2H), 2.05 (H-12, m, 2H), 3.89 (H-13, t (broad),
2H), 7.86 (H-16, m, 2H), 7.80 (H-17, m, 2H). 13C NMR (CDCl3) δ keto-enol form: 110.5 (C-1), 183.4
Int. J. Mol. Sci. 2019, 20, 28 15 of 21
(C-2), 120.4 (C-3), 141.6 (C-4), 134.2 (C-5), 111.9 (C-6), 151.4 (C-7), 141.9 (C-8), 121.2 (C-9), 123.2 (C-10)
23.9 (C-11), 31.5 (C-12), 38.2 (C-13), 168.7 (C-14), 134.8 (C-15), 123.4 (C-16), 134.7 (C-17).
(2-((4Z,6E)-5-hydroxy-7-(4-hydroxyphenyl)-4-((E)-3-(4-hydroxy-3-ethoxyphenyl) acryloyl)
hepta-4,6-dien-1-yl)isoindoline-1,3-dione (K3F31) Orange powder, 40% yield. Elemental analysis for
C30H25NO6: calc. C 72.72%, H 5.09%, N 2.83%) C 73.60%, H 5.21%, N 2.75%. LC-MS-IT m/z 496.6 (M +
H)+. 1H NMR (DMSO-d6) δ 7.00 (H-3, d (3JHH 15.9 Hz), 2H), 7.58 (H-4, d (3JHH 15.9 Hz), 2H), 7.54
(H-6/H-10, d (3JHH 8 Hz), 4H), 6.79 (H-7/H-9, d(3JHH 8 Hz), 4H), 2.65 (H-11, t (3JHH 7 Hz), 2H), 1.83
(H-12, m, 2H), 3.77 (H-13, t (broad), 2H), 7.88 (H-16, m, 2H), 7.85 (H-17, m, 2H). 13C NMR (DMSO-d6) δ
keto-enol form: 110.8 (C-1), 183.3 (C-2), 117.4 (C-3), 142.1 (C-4), 126.7 (C-5), 131.1 (C-6/C-10), 116.3
(C-7/C-9), 160.4 (C-8), 22.8 (C-11), 26.1 (C-12), 37.6 (C-13), 168.7 (C-14), 134.8 (C-15), 123.4 (C-16),
134.7 (C-17).
4.3. Acid-Base Behavior and Stability in Physiological Conditions
UV-vis spectrophotometric measurements were performed using Jasco V-570 spectrophotometer
at 25.0 ± 0.1 ◦C in the 200–600 nm spectral range employing 1 cm quartz cells. Owing to the poor
water solubility of the compounds, a methanol mother solution (5 × 10−3 M) was diluted in water in
order to give 50 µM solutions used for pH-metric titrations. The pH value was varied by adding small
amounts of concentrated NaOH or HCl, 25 points in the pH range 3–10. A constant ionic strength of
0.1 M (NaNO3) was maintained in all the experiments. Each titration was performed at least three
times. The overall protonation constants (logβLH) were evaluated from spectrophotometric data using
the software HypSpec [48].
Kinetic stability studies were performed at 37 ◦C in darkness, the change in absorbance in the
200−600 nm range over an overall period of 8 h was estimated for all the K3F samples by UV-vis
spectroscopy. 100 µM solutions of the ligands were prepared in 0.1 M Tris-HCl buffer (pH 7.4) with
constant ionic strength (0.1 M NaNO3). Spectra were recorded every 30 min. All profiles were linearized
by hyperbolic function (Equation (1)), which represents an empirical model that well describes drug
decomposition or release [49].
t/f% = at + b (1)
where f% is the fraction of residual compound at time t (min) expressed as percentage referred to
starting concentration at time zero.
4.4. Antioxidant Activity (DPPH Assay)
The antioxidant activity of the compounds was evaluated in terms of hydrogen donating or
radical scavenging ability, using the stable DPPH radical (1,1-diphenyl-2-picrylhydrazyl radical). A
variable amount (15, 30, 45, 75, 105, and 150 µL) of a methanol solution (1.2 mM) of each compound
was placed in a cuvette, and 3 mL of a 60 µM methanol solution of DPPH was added. Absorbance
measurements were initiated immediately. The decrease in absorbance at 517 nm was monitored
every minute up to 5′, then every 5′ up to 30′ and every 30′ until reaction reaches completion and
absorbance stabilizes attaining a plateau after 120′. Methanol was used to zero the spectrophotometer.
The absorbance of the DPPH radical without K3F compound, i.e., the control, was measured daily, and
concentration was calculated applying Equation (2) [50]
[DPPH·] =
A− 1.006
10970
(2)
The percentage of inhibition (%In) of the DPPH radical by each sample was calculated according
to the formula
%In =
A0 −At
A0
× 100 (3)
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where A0 represents the absorbance of the control (DPPH radical) at time 0, while At refers to the
absorbance of the mixture DPPH/antioxidant at time t (120 min). Values of absorbance were corrected
taking into account volume dilution and all determinations were performed in triplicate.
4.5. Cell Lines and Treatments
Human prostate cancer PC3 cells (CRL 1435, ATCC, Manassas, VA, USA) were grown in Ham’s
F12 nutrient medium, human prostate cancer DU145 cells (HTB-81, ATCC, Manassas, VA, USA) in
RPMI 1640 medium and human colorectal carcinoma HCT116 cells (CCL-247, ATCC, Manassas, VA,
USA) in IMDM medium. All media (Biowest, Nuaillé, France) were supplemented with 10% Foetal
Bovine Serum (Gibco-Thermo Fisher Scientific, Waltham, MA, USA), L-glutamine, penicillin, and
streptomycin (Euroclone, Milan, Italy), and grown at 37 ◦C in a humidified 5% CO2 atmosphere.
Synthesized curcumin, K3F compounds and docetaxel (MedChem Express, Monmouth Junction,
NJ, USA) were dissolved in DMSO (Sigma-Aldrich, St. Louis, MO, USA) and added to cell medium at
the concentrations described in the text for 48 h. DMSO was used as control. Docetaxel IC50 values
were calculated through MTT assay and estimated as 17 nM and 30 nM in DU145 and PC3, respectively.
4.6. Cell Viability Assay
The inhibition of cell proliferation was measured by colorimetric MTT assay [51] and the
concentration at which cellular growth is inhibited by 50% (GI50) was determined. Briefly, cells were
seeded into 96-well plates at a density of 2000 cells/well. The following day, cells were treated with the
indicated compounds and analyzed for cell viability after 48 h. 5 mg/mL thiazolyl blue tetrazolium
bromide (Sigma-Aldrich, St. Louis, MO, USA) was added to each well at a final concentration of 0.5
mg/mL and the plates were incubated at 37 ◦C for 2 h. Medium containing unconverted MTT was
removed and 100 µL MTT solvent (4 mM HCl, 0.1% NP-40 in isopropyl alcohol) was added to each
well. The plate was gently rotated on an orbital shaker in the dark for 15 min, before the measurements
of absorbance at 570 nm. The viability of untreated cells was arbitrarily set at 100%.
The ability of K3F21 and docetaxel to act synergistically with regard to growth inhibition was
determined using CompuSyn software (ComboSyn, Inc., freely available at http://www.combosyn.
com) [34]. Combination index (CI) and drug reduction index (DRI) were calculated for each
concentration of drugs mixture, as indicated in the text. CI <1, =1 or >1 indicates synergism, additive
effect, or antagonism, respectively. DRI >1 or <1 indicates favorable or not favorable dose-reduction.
4.7. Anchorage-Dependent and -Independent Colony Formation Assay
For anchorage-dependent colony formation assay, 1000 PC3 or 500 DU145 cells were plated
in 6-well plates. Following overnight incubation, the cells were treated with curcumin or K3F21
(2, 5, 10, 20 µM) or with DMSO, as control. After 7–10 days, the plates were washed, fixed and
stained with 0.5% crystal violet solution in 20% Methanol. Visible colonies with radius ≥3 pixels
were counted with automated colony counter (OpenCFU 3.9.0 software, freely available at http:
//opencfu.sourceforge.net/) and plotted against curcumin concentrations. Colony numbers were
normalized as a percentage of colonies formed following DMSO treatment.
For anchorage-independent colony formation assay, 0.6% low melt agarose gel with 10% FBS
in appropriate complete cell growth medium was prepared and added to the wells of a twelve-well
culture dish as a base agar. 1200 cells per well were plated in 0.25% (PC3) or 0.2% (DU145) agarose gel
in appropriate complete cell growth medium supplemented with varying concentrations of curcumin
and K3F21 (5, 10, 20 µM) or with DMSO, as control. PC3 and DU145 cells were allowed to grow at 37
◦C for three weeks (PC3) or five weeks (DU145). The effect of the drugs on anchorage-independent
growth was determined by colony growth. Colonies were stained with 0.07% crystal violet and
formed colonies were imaged. The numbers of colonies with radius ≥ 7 pixels were counted with
automated colony counter (OpenCFU 3.9.0) and average number of colonies was plotted against
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drug concentrations. Colony numbers were normalized as a percentage of colonies formed following
DMSO treatment.
4.8. Cell Cycle Analysis
Cells were harvested after 48 h drug treatments and DNA distribution analysis of cells stained
with propidium iodide solution (propidium iodide 25 µg/mL, Na-Citrate 3.4 mM, NaCl 9.65 mM,
NP-40 0.03%) was performed by an Epics cytofluorimeter (Beckman Coulter Srl, Milan, Italy) [52,53].
4.9. Cell Migration Assay
4 × 105 prostate cancer cells were plated in a 12-well plate. Approximately 24 h later, when the
cells were 100% confluent, the monolayer was scratched using a 200 µL pipette tip. Medium and
non-adherent cells were removed and new medium containing 1% FBS and GI50 concentrations of
Curcumin, K3F21 and DTX was added. Cells were observed under the microscope and the inhibition
of migration was assessed when the wound in the control was closed, after 16 h and 40 h in DU145 and
PC3, respectively. Three biological replicates were performed. Three random pictures were taken for
each treated well per experiment and the areas of the wounds measured using ImageJ software. The
percentage of wound recovery was then calculated using the formula: (final area-initial area)/initial
area × 100%.
4.10. Protein Extracts and Western Bot
Whole-cell protein extracts were prepared by resuspending cells into 1X SDS sample buffer (25 mM
Tris-HCl pH 6.8, 1.5 mM EDTA, 20% glycerol, 2% SDS, 5% β-mercaptoethanol, 0.0025% Bromophenol
blue). Equivalent amounts of cellular extracts were resolved by SDS-PAGE, electrotransferred to
PVDF membrane (GE Healthcare Italia, Milan, Italy) and immunoblotted with the following primary
antibodies: anti-phospo-H2AX (sc-101696), anti-p53 (DO1) (sc-126), anti-actin (I19) (sc-1616) and
anti-PARP (sc-8007) antibody from Santa Cruz Biotecnology, Inc, Dallas, TX, USA.; phospho-specific
AKT antibody S473 (#9018) and T308 (#9275), Akt antibody (#9272 and #2967), phospho-specific
ERK1/2 antibody T202/Y204 (#4370), ERK1/2 antibody (#4669), phospho-specific p38 MAPK antibody
T180/Y182 (#9211), and p38 antibody (#9212) were purchased from Cell Signaling Technologies,
Danvers, MA, USA. Membranes were blotted and scanned with Bio-Rad ChemiDocTM Touch Imaging
System (Bio-Rad, Hercules, CA, USA), using chemiluminescent detection reagents from Cyanagen,
Bologna, Italy (Westar ηC and Supernova HRP substrates for Western blotting).
4.11. RNA Extraction and RT-qPCR
RNA was extracted from cells using RNeasy kit (Qiagen, Venlo, The Netherlands) and reversed
transcribed with a Moloney murine leukemia virus reverse transcriptase (Promega, Madison, WI, USA).
Quantitative real-time PCRs were performed using SsoAdvanced Universal SYBR Green Supermix
(Bio-Rad, Hercules, CA, USA) on a Bio-Rad CFX Connect™ real-time PCR detection system. Primer
sequences are available upon request. The housekeeping gene Rpl21 was used as a loading control.
The relative fold change enrichments of real-time PCR samples were calculated with the formula
2−(∆∆Ct), where −(∆∆Ct) = −[(Ct target − Ct Rpl21)treated − (Ct target − Ct Rpl21)DMSO].
4.12. Statistical Analysis
Experiments were performed at least in biological triplicates and graphs represent mean ±
SEM values. All statistical analyses were performed using GraphPad PRISM v8 software (GraphPad
Software, La Jolla, CA, USA), using two-tailed t-tests or one-sample t-tests, as appropriate. p values
of p < 0.05 were considered to be statistically significant (*), p < 0.01 (**), p < 0.001 (***), and
p < 0.0001 (****).
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